Nanobodies (Nbs) are single-domain antibodies composed of variable heavy-chain domains (VHHs) derived from camelids. Their unique structure and superior properties have positioned them as a research hotspot in the global biopharmaceutical field.

Neurological diseases encompass a range of conditions that affect the normal functioning of the human nervous system, such as Alzheimer's disease, Parkinson's disease, and spinal cord injuries. These ailments significantly impact the quality of life and health of patients, causing profound suffering not only to those afflicted but also to their families and friends, casting enduring psychological shadows on all involved

Tumor. It's a name that still sends shivers down the spine worldwide. How to quickly detect, diagnose, and treat tumors has always been a major challenge in the medical field. With countless scientists and medical professionals continuously researching and discovering, nanobodies, as an emerging treatment strategy, have brought revolutionary changes to cancer treatment.

     Since the outbreak of the COVID-19 pandemic in 2020, the biopharmaceutical industry has encountered numerous challenges, marking one of the most turbulent periods in its history. The emergence and global spread of the COVID-19 pandemic have accelerated innovation and research processes within the biopharmaceutical sector.